PTAB institutes Lialda IPR, rejects Xyrem challenge
The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has instituted an inter partes review (IPR) petition from Kyle Bass' Coalition for Affordable Drugs challenging a patent for ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG) and denied the coalition's IPR challenge of a patent for narcolepsy drug Xyrem sodium oxybate from Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ).
PTAB instituted Bass' IPR challenge of U.S. Patent No. 6,773,720, which covers controlled-release oral compositions containing 5-aminosalicylate (5-ASA) and is owned by the Cosmo Technologies Ltd. subsidiary of Cosmo Pharmaceuticals S.p.A. (SIX:COPN). Shire plc markets Lialda, which is 5-ASA mesalamine formulated using Multi-Matrix system (MMX) technology from Cosmo. ...